MCID: OLG002
MIFTS: 59

Oligodendroglioma

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Oligodendroglioma

MalaCards integrated aliases for Oligodendroglioma:

Name: Oligodendroglioma 12 49 55 28 51 41 14 69
Oligodendroglial Neoplasm 12 69
Well Differentiated Oligodendroglioma 69
Oligodendroglial Tumors 51
Oligodendroglial Tumor 12

Characteristics:

Orphanet epidemiological data:

55
oligodendroglioma
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 55  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3181
MeSH 41 D009837
NCIt 46 C6960
Orphanet 55 ORPHA251627
UMLS via Orphanet 70 C0028945
ICD10 via Orphanet 33 C71.9

Summaries for Oligodendroglioma

NIH Rare Diseases : 49 Oligodendrogliomas are brain tumors arising from oligodendrocytes, a type of cell that makes up the supportive (glial) tissue of the brain. They can be low-grade (grade II) or high-grade (grade III, also called anaplastic). While they can be found anywhere within the cerebral hemisphere, they are most common in the frontal and temporal lobes. They are generally soft, grayish-pink tumors that often contain mineral deposits (calcifications), areas of hemorrhage, and/or cysts. They tend to grow slowly and may be present for many years before they are diagnosed. Common symptoms include seizures, headaches and changes in personality. Other symptoms vary by the size and location of the tumor. The exact cause of opigodendrogliomas is unknown. Some appear to have a chromosome abnormality involving loss of chromosomes 1p and 19q. Treatment generally involves surgical removal of the tumor followed by radiation therapy and/or chemotherapy. Recurrent tumors may need additional surgery, radiation and chemotherapy. Last updated: 8/8/2016

MalaCards based summary : Oligodendroglioma, also known as oligodendroglial neoplasm, is related to adult oligodendroglioma and childhood oligodendroglioma. An important gene associated with Oligodendroglioma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial), and among its related pathways/superpathways are Endometrial cancer and Neuroscience. The drugs Carmustine and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and temporal lobe, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Oligodendroglioma

Diseases in the Oligodendroglioma family:

Adult Oligodendroglioma

Diseases related to Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 252)
# Related Disease Score Top Affiliating Genes
1 adult oligodendroglioma 33.9 IDH1 IDH2
2 childhood oligodendroglioma 33.7 GFAP IDH1 OLIG2 SYP TP73
3 oligoastrocytoma 33.5 GFAP IDH2 MGMT
4 glioma susceptibility 1 33.5 IDH1 IDH2 TP53
5 anaplastic oligodendroglioma 33.2 CDKN2A CDKN2C EGFR IDH1 IDH2 MGMT
6 dysembryoplastic neuroepithelial tumor 31.1 GFAP IDH1 SYP
7 extraventricular neurocytoma 30.8 GFAP IDH1 SYP
8 central neurocytoma 30.8 ENO2 GFAP SYP
9 glioma 30.7 CDKN2A EGFR IDH1 IDH2 PDGFRA POT1
10 teratoma 30.5 ENO2 GFAP SYP TP53
11 ependymoma 30.5 EGFR GFAP MGMT SYP TP73
12 gemistocytic astrocytoma 30.3 GFAP IDH2 PTEN
13 gangliocytoma 30.3 GFAP PTEN SYP
14 angiocentric glioma 30.3 GFAP IDH1 SYP
15 cystic teratoma 30.2 ENO2 GFAP SYP TP53
16 astroblastoma 30.2 ENO2 GFAP SYP
17 astrocytoma 30.1 CDKN2A EGFR GFAP IDH1 MGMT OLIG2
18 pilocytic astrocytoma 30.0 CDKN2A GFAP IDH1 MGMT OLIG2 PTEN
19 ganglioglioma 30.0 ENO2 GFAP SYP TP53
20 clear cell ependymoma 30.0 ENO2 GFAP OLIG2 SYP TP53
21 meningioma, familial 29.9 CDKN2C GFAP PTEN SYP TP53 TP73
22 pleomorphic xanthoastrocytoma 29.9 GFAP IDH1 MGMT SYP TP53
23 cerebellar liponeurocytoma 29.6 ENO2 GFAP OLIG2 SYP TP53
24 mixed glioma 29.6 GFAP IDH1 PDGFRA TP53
25 juvenile pilocytic astrocytoma 29.6 CDKN2A ENO2 GFAP MBP TP53
26 neurilemmoma 29.4 ENO2 GFAP PDGFRA
27 gliosarcoma 29.4 EGFR ENO2 GFAP IDH1 MGMT PTEN
28 hydrocephalus 29.4 ENO2 GFAP MBP PTEN SYP TP53
29 glioblastoma 29.3 CDKN2A EGFR IDH1 IDH2 MGMT PDGFRA
30 medulloblastoma 28.7 ENO2 GFAP MGMT PDGFRA SYP TP53
31 brain cancer 28.6 EGFR ENO2 GFAP IDH1 IDH2 MGMT
32 glioblastoma multiforme 28.3 CDKN2A EGFR GFAP IDH1 MGMT PDGFRA
33 spinal cord oligodendroglioma 12.1
34 brain oligodendroglioma 12.1
35 corpus callosum oligodendroglioma 12.1
36 mixed oligodendroglioma-astrocytoma 12.1
37 mixed astrocytoma-ependymoma-oligodendroglioma 11.9
38 glioma susceptibility 2 10.9
39 glioma susceptibility 3 10.9
40 glioma susceptibility 9 10.9
41 interval angle-closure glaucoma 10.7 IDH1 IDH2
42 enchondroma 10.6 IDH1 IDH2
43 desmoplastic infantile ganglioglioma 10.6 GFAP SYP
44 adult astrocytic tumour 10.6 IDH1 IDH2 PTEN
45 periosteal chondrosarcoma 10.6 CDKN2A IDH1 IDH2
46 anaplastic ependymoma 10.6 GFAP PTEN SYP
47 lung combined type small cell carcinoma 10.6 GFAP SYP
48 breast papillary carcinoma 10.6 IDH1 IDH2 SYP
49 cerebellopontine angle tumor 10.6 GFAP IDH1 SYP
50 vulvar dystrophy 10.6 CDKN2A MBP

Graphical network of the top 20 diseases related to Oligodendroglioma:



Diseases related to Oligodendroglioma

Symptoms & Phenotypes for Oligodendroglioma

GenomeRNAi Phenotypes related to Oligodendroglioma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.06 EGFR
2 Decreased viability GR00173-A 10.06 PDGFRA
3 Decreased viability GR00221-A-1 10.06 EGFR PDGFRA CDKN2A CDKN2C POT1
4 Decreased viability GR00221-A-3 10.06 POT1 PDGFRA CDKN2A
5 Decreased viability GR00221-A-4 10.06 EGFR PDGFRA CDKN2A POT1
6 Decreased viability GR00301-A 10.06 CDKN2C
7 Decreased viability GR00342-S-2 10.06 CDKN2C
8 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 CIC PTEN TP53 TP73 NKX2-2 CDKN2A
9 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 CIC PTEN TP53 TP73 NKX2-2 CDKN2A
10 Decreased viability in esophageal squamous lineage GR00235-A 9.73 CIC PTEN TP53 GFAP IDH1 IDH2

MGI Mouse Phenotypes related to Oligodendroglioma:

43 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.38 PDGFRA OLIG1 OLIG2 MBP UGT8 TP53
2 growth/size/body region MP:0005378 10.38 NKX2-2 OLIG1 IDH1 OLIG2 MBP PDGFRA
3 cellular MP:0005384 10.34 PDGFRA NKX2-2 POT1 OLIG2 MBP TP53
4 mortality/aging MP:0010768 10.33 MGMT NKX2-2 POT1 OLIG1 IDH1 OLIG2
5 homeostasis/metabolism MP:0005376 10.27 MGMT PDGFRA NKX2-2 IDH1 MBP UGT8
6 nervous system MP:0003631 10.22 NKX2-2 OLIG1 OLIG2 MBP PDGFRA CDKN2C
7 immune system MP:0005387 10.17 PDGFRA IDH1 MBP UGT8 TP53 CDKN2C
8 endocrine/exocrine gland MP:0005379 10.15 MGMT PDGFRA NKX2-2 TP53 CDKN2C PTEN
9 embryo MP:0005380 10.11 PDGFRA POT1 NKX2-2 CDKN2A EGFR TP53
10 neoplasm MP:0002006 10.07 MGMT IDH2 OLIG2 PDGFRA TP53 CDKN2C
11 reproductive system MP:0005389 9.81 PDGFRA NKX2-2 MBP TP53 CDKN2C PTEN
12 respiratory system MP:0005388 9.73 IDH1 OLIG2 PDGFRA MGMT TP53 CDKN2C
13 pigmentation MP:0001186 9.65 PDGFRA CDKN2A EGFR TP53 PTEN
14 vision/eye MP:0005391 9.23 OLIG2 MBP TP53 GFAP PTEN TP73

Drugs & Therapeutics for Oligodendroglioma

Drugs for Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 358)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 3,Phase 1,Phase 2 154-93-8 2578
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
3
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
6
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
7
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
8
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
9
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
10 Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1 52-24-4 5453
11
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
12
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1 13010-47-4 3950
13
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
16
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
17
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
18
Ondansetron Approved Phase 3 99614-02-5 4595
19
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
20
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6, 75614-87-8 774
21
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
22
Methylphenidate Approved, Investigational Phase 3 20748-11-2, 113-45-1 4158
23
Isotretinoin Approved Phase 3,Phase 1 4759-48-2 5282379 5538
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
25
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
26
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 5538
27 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
28 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
29 Antimitotic Agents Phase 3,Phase 2,Phase 1
30 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
31 Antimetabolites Phase 3,Phase 2,Phase 1
32 Antimetabolites, Antineoplastic Phase 3,Phase 2
33 Antirheumatic Agents Phase 3,Phase 2,Phase 1
34 Dermatologic Agents Phase 3,Phase 1,Phase 2
35 Etoposide phosphate Phase 3,Phase 2,Phase 1
36 Folic Acid Antagonists Phase 3,Phase 2
37 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
38 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
39 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
40 Vitamin B Complex Phase 3,Phase 2,Phase 1
41 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
42 Liver Extracts Phase 3,Phase 2,Phase 1
43 Keratolytic Agents Phase 3,Phase 1,Phase 2
44 Adjuvants, Anesthesia Phase 3
45 Analgesics Phase 3,Phase 2,Phase 1
46 Analgesics, Opioid Phase 3
47 Anesthetics Phase 3,Phase 1
48 Anesthetics, General Phase 3
49 Anesthetics, Intravenous Phase 3
50 Narcotics Phase 3

Interventional clinical trials:

(show top 50) (show all 369)

# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
2 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
3 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
4 Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
5 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
6 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
7 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3 temozolomide
8 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
9 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
10 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
11 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
12 Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
13 gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas Recruiting NCT02444000 Phase 3 PCV chemotherapy alone;Radiotherapy+PCV chemotherapy
14 Phase III Trial of Anaplastic Glioma Without 1p/19q LOH Active, not recruiting NCT00626990 Phase 3 temozolomide
15 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Active, not recruiting NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
16 Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Active, not recruiting NCT00978458 Phase 3 temozolomide
17 Treatment Strategy for Low-grade Gliomas Terminated NCT00897377 Phase 3 Temozolomide
18 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
19 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
20 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
21 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
22 A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas Unknown status NCT02209428 Phase 2 Temozolomide
23 A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma Unknown status NCT00683761 Phase 1, Phase 2 131I-TM601
24 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT00004204 Phase 2 temozolomide
25 Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
26 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
27 Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma Unknown status NCT00360945 Phase 2 cisplatin;temozolomide
28 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
29 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
30 Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
31 Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
32 Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma Completed NCT00003101 Phase 2 busulfan;lomustine;procarbazine hydrochloride;thiotepa;vincristine sulfate
33 Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma Completed NCT00400816 Phase 2 temozolomide
34 Temozolomide in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00003465 Phase 2 temozolomide
35 Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma Completed NCT00004024 Phase 2
36 Topotecan in Treating Patients With Recurrent Brain Tumors Completed NCT00003372 Phase 2 topotecan hydrochloride
37 Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma Completed NCT01663012 Phase 2 Etirinotecan pegol
38 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
39 Prolonged Daily Temozolomide for Low-Grade Glioma Completed NCT00165360 Phase 2 Temozolomide
40 Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma Completed NCT00823459 Phase 2 RAD001
41 Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) Completed NCT00615927 Phase 2 Imatinib Mesylate & Hydroxyurea
42 Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors Completed NCT00667394 Phase 2 MLN-518 (Tandutinib)
43 Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors Completed NCT00003304 Phase 2 temozolomide
44 Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors Completed NCT00012038 Phase 1, Phase 2 irofulven
45 Procarbazine in Treating Patients With Recurrent Brain Tumor Completed NCT00004004 Phase 1, Phase 2 procarbazine hydrochloride
46 Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors Completed NCT00003731 Phase 2 temozolomide
47 Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma Completed NCT00575887 Phase 2 Temozolomide
48 The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) Completed NCT00392171 Phase 2 Temozolomide
49 A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis Completed NCT00565721 Phase 2 Fluciclatide Injection - (AH111585 (F18))
50 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2 carmustine;mercaptopurine;streptozocin

Search NIH Clinical Center for Oligodendroglioma

Cochrane evidence based reviews: oligodendroglioma

Genetic Tests for Oligodendroglioma

Genetic tests related to Oligodendroglioma:

# Genetic test Affiliating Genes
1 Oligodendroglioma 28

Anatomical Context for Oligodendroglioma

MalaCards organs/tissues related to Oligodendroglioma:

38
Brain, Spinal Cord, Temporal Lobe, Bone, Bone Marrow, T Cells, Endothelial

Publications for Oligodendroglioma

Articles related to Oligodendroglioma:

(show top 50) (show all 715)
# Title Authors Year
1
Outcomes and Prognostic Factors in Pediatric Oligodendroglioma: A Population-Based Study. ( 29131101 )
2018
2
Focal Cortical Dysplasia Type IIIb with Oligodendroglioma in a Seizure-Free Patient. ( 29429417 )
2018
3
Holocord oligodendroglioma with intracranial extension in a young adult: a case report and review of literature. ( 29390865 )
2018
4
Predictors of clinical outcome in pediatric oligodendroglioma: meta-analysis of individual patient data and multiple imputation. ( 29192869 )
2018
5
Cerebellar Peduncle Localized Oligodendroglioma: A Case Report and Review of the Literature. ( 29438788 )
2018
6
Enchondromatosis-associated oligodendroglioma: case report and literature review. ( 29224049 )
2018
7
MR textural analysis on T<sub>2</sub>FLAIR images for the prediction of true oligodendroglioma by the 2016 WHO genetic classification. ( 29140606 )
2017
8
A Case of Anaplastic Oligodendroglioma With Extensive Extraneural Metastases Imaged With FDG PET. ( 29076897 )
2017
9
Multicentric high grade oligodendroglioma: a rare entity. ( 29078728 )
2017
10
Pinpointing Cancer Stem Cells in Oligodendroglioma. ( 27864226 )
2017
11
Clinical, radiological, pathological and prognostic aspects of intraventricular oligodendroglioma: comparison with central neurocytoma. ( 28900829 )
2017
12
Genetic landscape of extreme responders with anaplastic oligodendroglioma. ( 28388591 )
2017
13
Multimodal (18)F-Fluciclovine PET/MRI and Ultrasound-Guided Neurosurgery of an Anaplastic Oligodendroglioma. ( 28844925 )
2017
14
A Case of Congenital Brainstem Oligodendroglioma: Pathology Findings and Review of the Literature. ( 28815096 )
2017
15
Vessel morphometric parameters-correlation with histologic grade and VEGF expression in oligodendroglioma. ( 28469969 )
2017
16
IMAGING DIAGNOSIS -ANTEMORTEM DETECTION OF OLIGODENDROGLIOMA "CEREBROSPINAL FLUID DROP METASTASES" IN A DOG BY SERIAL MAGNETIC RESONANCE IMAGING. ( 28176389 )
2017
17
Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted. ( 28812310 )
2017
18
Pica in a Child with Anterior Cingulate Gyrus Oligodendroglioma: Case Report. ( 28704833 )
2017
19
Characterization of brain tumours with spin-spin relaxation: pilot case study reveals unique T 2 distribution profiles of glioblastoma, oligodendroglioma and meningioma. ( 28894952 )
2017
20
Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis. ( 28498059 )
2017
21
Metastatic grade III oligodendroglioma revealed by refractory thrombocytopenia. ( 28737366 )
2017
22
Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature. ( 28696020 )
2017
23
Osteosclerosis Secondary to Metastatic Oligodendroglioma. ( 28435646 )
2017
24
Vascular Endothelial Growth Factor as an Angiogenic Marker in Malignant Astrocytoma and Oligodendroglioma: An Indian Scenario. ( 28384867 )
2017
25
Cerebellar Cystic Oligodendroglioma in a Young Adult. ( 28694642 )
2017
26
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. ( 28472509 )
2017
27
A very rare spinal cord tumor primary spinal oligodendroglioma: A review of sixty cases in the literature. ( 29021677 )
2017
28
Diffuse Infiltrating Oligodendroglioma and Astrocytoma. ( 28640702 )
2017
29
Synchronous gemistocytic astrocytoma IDH-mutant and oligodendroglioma IDH-mutant and 1p/19q-codeleted in a patient with CCDC26 polymorphism. ( 28550371 )
2017
30
Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI. ( 28126746 )
2017
31
CNS cancer: Tracing stem cells in oligodendroglioma. ( 27874063 )
2017
32
142a88Genetic and Nongenetic Determinants of Cellular Architecture in IDH1-Mutant Oligodendrogliomas and Astrocytomas Using Single-Cell Transcriptome Analysis. ( 27399421 )
2016
33
Racial disparities in anaplastic oligodendroglioma: An analysis on 1643 patients. ( 28024733 )
2016
34
The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients. ( 27651340 )
2016
35
Granular cells in oligodendroglioma suggest a neoplastic change rather than a reactive phenomenon: case report with molecular characterisation. ( 27738816 )
2016
36
Temozolomide induces radiologic pseudoprogression and tumor cell vanishing in oligodendroglioma. ( 27251883 )
2016
37
Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups. ( 26757882 )
2016
38
Case 38-2016. A 52-Year-Old Woman with Recurrent Oligodendroglioma. ( 27974037 )
2016
39
Synchronous thymoma and oligodendroglioma: A rare association. ( 26957188 )
2016
40
Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. ( 27812792 )
2016
41
IMAGING DIAGNOSIS-MAGNETIC RESONANCE IMAGING FEATURES OF A MULTIFOCAL OLIGODENDROGLIOMA IN THE SPINAL CORD AND BRAIN OF A DOG. ( 27490488 )
2016
42
Low-grade and anaplastic oligodendroglioma. ( 26948366 )
2016
43
Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma. ( 26722084 )
2016
44
Papilloedema secondary to oligodendroglioma. ( 27489047 )
2016
45
Radiological imaging features of glioblastoma with oligodendroglioma component: a comparison with conventional glioblastoma. ( 27900202 )
2016
46
High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma. ( 26960282 )
2016
47
A rare presentation of anaplastic oligodendroglioma metastatic to bone marrow, mimicking blast cells. ( 27302043 )
2016
48
Cytokine-induced release of ceramide-enriched exosomes as a mediator of cell death signaling in an oligodendroglioma cell line. ( 27623848 )
2016
49
Molecular Analysis of Pediatric Oligodendrogliomas Highlights Genetic Differences with Adult Counterparts and Other Pediatric Gliomas. ( 26206478 )
2016
50
Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. ( 27806376 )
2016

Variations for Oligodendroglioma

ClinVar genetic disease variations for Oligodendroglioma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388

Copy number variations for Oligodendroglioma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13342 1 1 124300000 Loss Oligodendroglial tumors
2 42816 10 40300000 135374737 Loss Oligodendroglial tumors
3 119741 18 16100000 76117153 Loss Oligodendroglial tumors
4 124095 19 1 28500000 Gain Oligodendroglial tumors
5 127178 19 28500000 63811651 Loss Oligodendroglial tumors
6 187538 4 50700000 191273063 Loss Oligodendroglial tumors
7 217108 7 1 59100000 Gain Oligodendroglial tumors
8 226562 7 59100000 158821424 Gain Oligodendroglial tumors
9 244959 9 1 51800000 Loss Oligodendroglial tumors

Expression for Oligodendroglioma

Search GEO for disease gene expression data for Oligodendroglioma.

Pathways for Oligodendroglioma

Pathways related to Oligodendroglioma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.91 CDKN2A CDKN2C EGFR PDGFRA PTEN TP53
2 12.47 ENO2 GFAP MBP NKX2-2 SYP
3 12.37 CDKN2A EGFR PDGFRA PTEN TP53
4 12.34 CDKN2A CDKN2C MGMT TP53 TP73
5 12.28 CDKN2A CDKN2C PDGFRA TP53
6
Show member pathways
12.23 CDKN2A PTEN TP53 TP73
7 11.95 EGFR PTEN TP53 TP73
8 11.93 CDKN2A MGMT PTEN TP53
9 11.84 EGFR GFAP MBP TP53
10 11.77 CDKN2A PTEN TP53 TP73
11 11.68 GFAP MBP OLIG1 OLIG2
12 11.6 CDKN2A EGFR TP53
13 11.48 CDKN2A EGFR MGMT PDGFRA PTEN TP53
14 11.37 EGFR IDH1 PDGFRA PTEN TP53
15 11.27 CDKN2A EGFR PDGFRA TP53
16 11.11 CDKN2A CDKN2C TP53
17 11 GFAP NKX2-2 OLIG1 OLIG2 PDGFRA SYP
18
Show member pathways
10.84 CDKN2A TP53 TP73
19
Show member pathways
10.7 IDH1 IDH2

GO Terms for Oligodendroglioma

Biological processes related to Oligodendroglioma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 cell cycle arrest GO:0007050 9.73 CDKN2A CDKN2C TP53 TP73
2 negative regulation of neuron differentiation GO:0045665 9.65 NKX2-2 OLIG2 TP73
3 cellular response to reactive oxygen species GO:0034614 9.58 EGFR PDGFRA TP53
4 replicative senescence GO:0090399 9.52 CDKN2A TP53
5 negative regulation of telomerase activity GO:0051974 9.51 POT1 TP53
6 mitotic G1 DNA damage checkpoint GO:0031571 9.49 TP53 TP73
7 isocitrate metabolic process GO:0006102 9.46 IDH1 IDH2
8 oligodendrocyte differentiation GO:0048709 9.43 CDKN2C OLIG1 OLIG2
9 spinal cord oligodendrocyte cell differentiation GO:0021529 9.37 NKX2-2 OLIG2
10 spinal cord oligodendrocyte cell fate specification GO:0021530 9.32 NKX2-2 OLIG2
11 glyoxylate cycle GO:0006097 9.16 IDH1 IDH2
12 positive regulation of oligodendrocyte differentiation GO:0048714 9.13 NKX2-2 OLIG2 TP73
13 response to organic cyclic compound GO:0014070 9.1 EGFR IDH1 MGMT NKX2-2 PTEN TP53

Molecular functions related to Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 EGFR GFAP IDH1 PTEN SYP TP53
2 chromatin binding GO:0003682 9.77 CIC EGFR NKX2-2 TP53 TP73
3 magnesium ion binding GO:0000287 9.71 ENO2 IDH1 IDH2 PTEN
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.46 CDKN2A CDKN2C
5 MDM2/MDM4 family protein binding GO:0097371 9.32 TP53 TP73
6 isocitrate dehydrogenase activity GO:0004448 9.16 IDH1 IDH2
7 protein kinase binding GO:0019901 9.1 CDKN2A CDKN2C EGFR PTEN TP53 TP73
8 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH1 IDH2
9 DNA binding GO:0003677 10.09 CDKN2A CIC MGMT NKX2-2 OLIG1 OLIG2

Sources for Oligodendroglioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....